Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sumit Garg

Cornea and External Diseases Specialist Irvine, CA Medical Doctor

NPI 1881878262 CMS profile 40512

850 Health Sciences Rd, Irvine, CA 92617

Open in the dashboard

General payments

$807,981

720 records reported · program years 2019–2025

Research payments

$7,862

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$30

2 holdings reported · through program year 2025

Research they led as principal investigator

$64,809 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Sumit Garg of Irvine, CA is reported in the CMS Open Payments database as having received $807,981 across 720 general payments and $7,862 in research payments paid to them. Separately, studies naming them as principal investigator received $64,809 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $30 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $178,849 108
2024 General $70,141 89
2023 General $63,471 71
2022 General $104,324 104
2021 General $82,111 100
2021 Research $7,862 1
2020 General $148,798 126
2019 General $160,289 122
2021 Ownership $15 1
2020 Ownership $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sumit Garg
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Sumit Garg were reported at $178,849. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Sumit Garg Cornea and External Diseases Specialist median Middle half National median
2019 $160,289 $276 $111–$734 $163
2020 $148,798 $146 $48–$330 $114
2021 $82,111 $254 $116–$566 $132
2022 $104,324 $251 $106–$729 $149
2023 $63,471 $344 $149–$759 $160
2024 $70,141 $366 $170–$927 $164
2025 $178,849 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $332,660 249 payments
  2. VisionCare Inc. $96,511 26 payments
  3. Beaver-Visitec International, Inc. $92,227 6 payments
  4. Allergan Inc. $41,434 65 payments
  5. Novartis Pharmaceuticals Corporation $39,708 34 payments
  6. Sight Sciences, Inc. $34,606 45 payments
  7. Dompe US, Inc. $33,985 39 payments
  8. Glaukos Corporation $28,706 52 payments
  9. AbbVie, Inc. $22,897 26 payments
  10. Kala Pharmaceuticals, Inc. $16,338 21 payments
  11. Other $68,909 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $668,523 233 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,350 35 payments
  3. Food and Beverage $24,225 384 payments
  4. Honoraria $18,626 14 payments
  5. Travel and Lodging $16,440 41 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $5,600 8 payments
  7. Grant $5,000 1 payment
  8. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $4,000 2 payments
  9. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,200 1 payment
  10. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. Compact Intuitiv $138,344 40 payments
  2. INTRALASE FS FEMTOSEC LASER $138,344 40 payments
  3. IFS ADVANCED FEMTOSEC LASER $134,444 38 payments
  4. Implantable Miniature Telescope $90,011 25 payments
  5. Catalys Laser System $73,163 35 payments
  6. COMPACT INTUITIV Phacofragmentation System $72,725 22 payments
  7. Tecnis IOL $43,885 36 payments
  8. Tecnis Multifocal Family of 1-piece IOLS $25,369 21 payments
  9. XIIDRA $25,025 24 payments
  10. VUITY $20,908 23 payments
  11. Other $314,028 667 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $7,862 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,405

Median for Ophthalmology: 891

Drug cost

$238,853

Median for Ophthalmology: $68,233

Branded share of claims

38.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xiidra Lifitegrast Brand 71 $92,311
Restasis Cyclosporine Brand 93 $84,582
Miebo Perfluorohexyloctane/Pf Brand 17 $15,602
Cyclosporine Generic 45 $15,466
Prednisolone Acetate Generic 373 $12,267
Moxifloxacin Moxifloxacin Hcl Brand 271 $5,733
Loteprednol Etabonate Generic 26 $3,368
Ketorolac Tromethamine Generic 236 $2,957
Fluorometholone Generic 34 $1,918
Dorzolamide-Timolol Dorzolamide/Timolol/Pf Brand 11 $1,817

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$467,490

Medicare's payments for the services billed

Medicare patients

1,256

Average age 76

Services billed

3,936

702 women, 554 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Ischemic heart disease 27%
Osteoporosis 25%
Diabetes 24%
Chronic kidney disease 18%
Cancer 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Omidria
  • Rayner Intraocular Lenses Limited $3,098
$3,098 — —
MIEBO
  • Bausch & Lomb Americas Inc. $455
$455 17 —
XIIDRA
  • Bausch & Lomb Americas Inc. $455
$455 71 —
OXERVATE
  • Dompe US, Inc. $224
$224 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $214
$214 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

721 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record